title: Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.
abstract: BACKGROUND
  The objective of the current study was to evaluate the efficacy of intensive chemotherapy with and without cranial radiation for central nervous system (CNS) prophylaxis in adults with Burkitt leukemia or lymphoma.
  
  
  METHODS
  Patients received 18 weeks of therapy. Prophylactic cranial radiation (2400 centigrays) and 12 doses of triple intrathecal chemotherapy were administered to the first cohort of patients. A subsequent cohort received the same therapy, with the exceptions that intrathecal therapy was reduced to six doses and radiotherapy was administered only to high-risk individuals.
  
  
  RESULTS
  The median follow-up durations were 6.8 years in Cohort 1 and 4.1 years in Cohort 2. Three occurrences of transverse myelitis, 2 severe neuropathies, 3 cases of aphasia, and 1 case of blindness were documented in the first cohort of 52 patients (Cohort 1). In the subsequent cohort of 40 patients (Cohort 2), none of these occurrences were observed, and patients experienced less neurologic toxicity overall (61% vs. 26%; P=0.001). Responses were similar, and the 3-year event-free survival rate was 0.52 (95% confidence interval, 0.38-0.65) for Cohort 1 and 0.45 (0.29-0.60) for Cohort 2.
  
  
  CONCLUSIONS
  Intensive, short-duration chemotherapy with less intensive CNS prophylaxis led to control at this sanctuary site with little neurotoxicity and may be curative for adults with Burkitt leukemia or lymphoma.
authors.affiliation: Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. rizzi003@mc.duke.edu
authors.forename: David A
authors.initials: DA
authors.lastname: Rizzieri
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Johnson
authors.forename: Donna
authors.initials: D
authors.lastname: Niedzwiecki
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Lee
authors.forename: James W
authors.initials: JW
authors.lastname: Vardiman
authors.forename: Bayard L
authors.initials: BL
authors.lastname: Powell
authors.forename: Maurice
authors.initials: M
authors.lastname: Barcos
authors.forename: Clara D
authors.initials: CD
authors.lastname: Bloomfield
authors.forename: Charles A
authors.initials: CA
authors.lastname: Schiffer
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Peterson
authors.forename: George P
authors.initials: GP
authors.lastname: Canellos
authors.forename: Richard A
authors.initials: RA
authors.lastname: Larson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D003520:Cyclophosphamide; D008727:Methotrexate